Furthermore, in Figure 2, Kaplan–Meier analyses of OS demonstrated that STAM1 downregulation is an ideal biomarker in predicting worse survival in progressed ccRCC patients compared with early-stage cancer. The gene discussed is STAM; the disease is nonpapillary renal cell carcinoma.